NEW YORK –BTIG said Monday that it has initiated coverage of diagnostics firm Oncocyte with a Buy rating and a price target of $5 per share.
Oncocyte's product offerings include DetermaRx, a tissue-based gene expression test intended to inform therapeutic decisions in early-stage lung cancer, and the currently research-use-only DetermaIO, which assesses the tumor microenvironment to predict immunotherapy response.